Observational studyPloS one2020

C-reactive protein can predict dose intensity, time to treatment failure and overall survival in HCC treated with lenvatinib.

Tsuguru Hayashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.